Clinical pharmacokinetics of XXXX .

@entity1 @entity8 @entity137 @entity191 @entity683 @entity7776
@entity7776 is a drug with diverse uses ranging from prevention of @entity683 A illness to the treatment of @entity1 with @entity191 . It is available only in oral formulations from which it is well absorbed and widely distributed, little drug being present in the circulation. Apparent volume of distribution is inversely related to dose over the therapeutic range and accounts in part for a noteworthy logarithmic increase in plasma concentration as a function of dose. Elimination is primarily by renal clearance by both glomerular filtration and tubular secretion. @entity7776 accumulates in @entity1 with @entity8 . Hence, doses must be reduced in such @entity1 to avoid @entity137 . Interactions with other drugs appear uncommon. Relationships have been demonstrated between @entity7776 therapeutic effects and plasma concentrations in different study cohorts, but not in individual @entity1 . Dose schedules have been suggested for individuals in whom @entity7776 kinetics are different from healthy subjects. However, these schedules are controversial in their choice of target concentrations and in being untested as to predictive value.
